Jie Lu1†
Kun Sun2†Huiping Yang1Dan Fan1He Huang2Yi Hong3Shuiyan Wu1
HuiTing Zhou4Fang Fang4YanHong Li4,5Lijun Meng1Jie Huang6*Zhenjiang Bai1*- 1Department of Pediatric Intensive Care Unit, Children Hospital of Soochow University, Suzhou, China
- 2Department of Emergency, Xuzhou Children’s Hospital, Xuzhou Medical University, Xuzhou, China
- 3Department of Pediatrics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China
- 4Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, China
- 5Department of Nephrology, Children’s Hospital of Soochow University, Suzhou, China
- 6Department of Cardiovascular Medicine, Children Hospital of Soochow University, Suzhou, China
Background: Sepsis is a complex systemic immune dysfunction syndrome induced by infection. Sepsis has a high mortality rate, with most patients dying due to systemic organ failure or secondary infection. Dendritic cells (DCs) are professional antigen-presenting cells. Upon infection with microbes, DCs are activated to induce adaptive immune responses for controlling infection. DC generation and function are impaired during sepsis; however, the underlying mechanisms remain largely unknown.
Methods: Peripheral blood samples from sepsis patients were collected to examine DC subsets, DC progenitors, and apoptosis of DCs by flow cytometer. In vitro induction of DCs from hematopoietic stem/progenitor cells were established and a variety of sepsis-associated inflammatory mediators [e.g., interferon-gamma (IFN-γ), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α) and granulocyte-colony stimulating factor (G-CSF)] and Lipopolysaccharide (LPS) were determined for the impact on DC generation and function in vitro.
Results: Our results demonstrate that sepsis-induced systemic inflammation impairs the capacity of hematopoietic stem and progenitor cells (HSPCs) to produce DCs, including conventional DCs (cDCs) and plasmacytoid DCs (pDCs). We investigated peripheral blood (PB) samples from 34 pediatric patients on days 1 to 7 following diagnosis. Compared to healthy donors (n = 18), the sepsis patients exhibited a significantly fewer percentage and number of pDCs and cDCs, and a lower expression of antigen presenting molecule HLD-DR and co-stimulatory molecules (e.g., CD86) on the surface of DCs. This sepsis-induced DC impairment was associated with significantly increased apoptotic death of DCs and marked decreases of progenitor cells that give rise to DCs. Furthermore, we observed that among the tested sepsis-associated cytokines (e.g., IFN-γ, IL-1β, TNF-α, and G-CSF), G-CSF and IFN-γ impaired DC development from cultured HSPCs. G-CSF also markedly decreased the expression of HLA-DR on HSPC-derived DCs and their cytokine production, including IL-12 and IFN-β.
Conclusions: Collectively, these findings indicate that sepsis impairs the survival of functional DCs and their development from HSPCs. Strategies for improving DC reconstitution following sepsis may restore DC progenitors and their associated function.
Introduction
Sepsis is a form of life-threatening organ dysfunction due to a dysregulated host immune response to infection (1). In 2017, an estimated 48.9 million cases of sepsis were recorded worldwide, with 11.0 million sepsis-related patient deaths, representing 19.7% of all global deaths (2). Dendritic cells (DCs) are the most potent antigen presentation cells (APCs), which play an essential role in the pathogen recognition, regulation of immune response, and inflammation (3, 4), and link both the innate and adaptive immunity (5, 6). DCs are mainly classified as conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) in peripheral blood (7). DC defects and dysfunction represent an important contributor to persistent inflammation, immunosuppression, susceptibility to infection and death in sepsis patients (8). An autopsy analysis has shown that adult sepsis patients have fewer DCs in the blood and spleen compared to non-sepsis patients (6, 9, 10). In addition, sepsis patients with low DC counts are susceptible to nosocomial infections (11), suggesting the DC compartment may play an important role during sepsis progression. However, there is limited clinical data regarding DC generation and function in the acute inflammatory phase in children with sepsis. A more in-depth understanding of the mechanisms by which DC generation and function are impaired during and after sepsis will be important for improving the outcomes of sepsis therapy.
Sepsis induces a systemic dysregulated inflammatory response that is characterized by the excessive production of inflammatory mediators [e.g., interleukin-1β (IL-1β), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), granulocyte-Colony stimulating factor (G-CSF), interleukin-10 (IL-10) and transforming growth factor-β (TGF-β)] and the inflammatory inducer [lipopolysaccharide (LPS)] (12). Accumulating evidence indicates that inflammatory factors cause DC impairment, dysfunction, and apoptosis (13–22). DCs develop from hematopoietic stem/progenitor cells (HSPCs) in the human bone marrow (BM) through successive lineage commitment and differentiation steps: multipotent progenitors (MPPs); common myeloid progenitors (CMPs); granulocyte macrophage DC progenitors (GMDPs); monocyte and DC progenitors (MDPs); and common DC progenitors (CDPs) (23, 24). Under a pathological microenvironment, DC development in the bone marrow (BM) may have been dramatically changed in response to inflammatory stimuli (25). The level of the pro-inflammatory factors G-CSF and IFN-γ, are low under steady state conditions, but were elevated in response to inflammatory stimuli (26–29). Moreover, elevated levels of G-CSF and IFN-γ have been reported to be associated with a poor clinical outcome in sepsis (30–34). Several studies have shown that inflammation may inhibit the regenerative capacity of HSCs and DC progenitor cells (35–37). However, whether the de novo generation of DCs from HSPCs is impaired in sepsis within this complex internal environment remains largely unknown.
In the present study, we examined the DC survival capability and DC progenitors in the peripheral blood (PB) of sepsis patients. Sepsis severely impairs the generation of CDPs and depletes DCs in the PB of pediatric patients. We found that among sepsis-associated inflammatory cytokines (e.g., IL-1β, IFN-γ, TNF-α and G-CSF) and LPS, G-CSF and IFN-γ were found to significantly reduce DC development and functional differentiation. These findings identify a previously uncharacterized mechanism by which sepsis impairs DC generation and function. Strategies to improve DC reconstitution following sepsis may be required to restore DC progenitors and their function.
Methods
Healthy Donors and Patients
The present study was conducted in the pediatric intensive care unit (ICU) of the Children’s Hospital of Soochow University. A total of 34 critically ill patients with sepsis were enrolled from January 2020 to April 2021. The sepsis patients’ demographic is shown in Table 1. The sepsis patients were further divided into two groups based on the time following diagnosis: early stage (days 1−2, n = 27) and later (days 3−7, n = 13). This study was approved by the Medical Ethics Committee of the Children’s Hospital of Soochow University (Suzhou, China). Written informed consent was obtained from children with sepsis (or their parents) upon their initial admission to the hospital and from healthy volunteers.
Table 1 Characteristics of the 34 children with sepsis included in the study.
Inclusion and Exclusion Criteria
Pediatric patients with sepsis were included in this study if they met the diagnostic criteria for sepsis (1, 38). Patients were excluded from the study if they had the following diseases: congenital immunodeficiency disease; immunodeficiency caused by human immunodeficiency virus (HIV) infection; BM or solid organ transplantation; hematologic malignancy; and allergic diseases (e.g., asthma).
Cell Isolation and Flow Cytometry
Fresh leukocytes were isolated from the peripheral blood (PB) after using red blood cell lysis buffer (Solarbio, Beijing, China). Samples were incubated with fluorescence-labeled antibodies for the directed analysis on the Attune NxT Flow Cytometer (Life Technologies, CA, USA). All mAbs used for fluorescence staining were purchased from Biolegend (San Diego, CA) or Invitrogen (Carlsbad, CA) (Table 2). mAb staining was performed as previously described (39). Total DCs were characterized as negative for lineage markers (CD3, CD14, CD15, CD16, CD19, and CD56) and positive for HLA-DR. Among these cells, CD1c+ cells were defined as conventional DCs (CD1c+ cDCs), whereas CD123+CD1c-CD11c- cells were defined as plasmacytoid dendritic cells (pDCs) (7). HSPCs were labelled as CD34+ cells. Human common DC progenitors (CDPs) were identified as CD34+CD38-CD10-CD45RA+CD123+CD115-. Human monocyte-DC progenitors (MDPs) were characterized as CD34+CD38-CD10-CD45RA+CD123intCD115-. Human granulocyte-monocyte DC progenitors (GMDPs) were marked as CD34 +CD38-CD10-CD45RA+CD123intCD115+ (40).
Table 2 Antibodies.
Detection of Apoptosis
The evaluation of apoptotic cells was examined using FITC-conjugated Annexin-V and propidium iodide (PI) kits (Invitrogen, Carlsbad, CA). Living (Annexin-V−PI−), early apoptotic (Annexin-V+PI−) and late apoptotic or necrotic (Annexin-V+PI+) cells were distinguished.
DC Induction and Generation From HSPCs
All recombinant cytokines were purchased from PeproTech (PeproTech, NJ). HSPCs were purified from G-CSF mobilized human PB using CD34+ microbeads (Miltenyi, 130046702) in accordance with the manufacturer’s instructions. To induce DCs, HSPCs were first cultured in Roswell Park Memorial Institute (RPMI) 1640 containing 10% fetal bovine serum (Dongling Biotech), FMS-like tyrosine kinase 3 ligand (FLT3L) (100 ng/mL), stem cell factor (SCF) (20 ng/mL), interleukin-3 (IL-3) (20 ng/mL), and thermoplastic polyolefin (TPO) (20 ng/mL) for 7 days, followed by additional culture for 7 days following the removal of TPO. On day 14, the cells were collected for analysis. To test the impact of inflammatory mediators [e.g., IFN-γ (10ng/ml), IL-1β (10ng/ml), G-CSF (10ng/ml) and TNF-α (10ng/ml)] and LPS (10ng/ml) on DC development, we cultured HSPCs as described above with or without addition of the inflammatory cytokines and the inducer as described above. To induce DC activation, we added LPS (100 ng/mL, Sigma), R848 (100 ng/mL, Invitrogen) or CpG oligonucleotide (CPG ODN) (1 μM) into the DC population or fluorescence-activated cell sorting (FACS)-sorted purified DC population using a BD Influx or BD FACs Aria II.
Real-Time RT- PCR
Total RNA was extracted from DCs derived from HSPCs in vitro using Trizol (Invitrogen) according to the manufacturer’s instructions. Reverse-transcription was performed using a >commercial kit with random primers (Takara). Complementary DNA (cDNA) was quantified through quantitative real-time polymerase chain reaction (PCR) using a SYBR Green PCR mix (Takara) on a LightCycler 480 PCR System (Roche). The thermocycler conditions included an initial hold period at 95°C for 10 min, followed by a three-step PCR program, as follows: 95°C for 20s, 55°C for 30s, and 72°C for 30s for 40 cycles. Transcript abundance was calculated using the delta Ct method (normalization with 18S). All of the primer sequences are listed in Table 3.
Table 3 Primer for real-time RT-PCR.
Statistics
Statistical analysis was performed using Graph Pad Prism 8 software (San Diego). Continuous data were expressed as the mean ± standard deviation (S.D.). Data conforming to a normal distribution were compared using a two-tailed t test, whereas non-normally distributed data were evaluated using a Mann-Whitney U-test. A threshold of p < 0.05 was considered to be statistically significant.
Results
Sepsis Induces a Selective Reduction of DCs in Pediatric Patients
To identify the effect of sepsis on DCs, we obtained PB from sepsis patients (n = 34) (Table 1). We focused on CD1c+ DCs (CD1c+CD123-CD11c+) and pDCs (CD1c-CD123+CD11c-) (Figure 1A), which represent the majority of the DCs found in the PB (7). PB from normal healthy donors (n = 18) was assessed as a control. Both the percentage and number of CD1c+ DCs and pDCs significantly declined in sepsis patients during the first two days following diagnosis compared to that of the healthy donors (Figures 1B−D). There was approximately an 8- to 10-fold reduction in both the frequency and number of CD1c+DCs and pDCs out of the total leukocytes of sepsis patients compared to that of the healthy donors (Figures 1B, D). Notably, this DC-associated defect in the sepsis patients persisted throughout 7 days after disease onset (Figures 1B−D). Sepsis did not significantly alter the frequency of monocytes in the PB throughout 7 days when DCs were decreased (Figure 1E). These data indicate that sepsis causes severe DC defects in the PB early after disease onset and does not recover within 7 days.
Figure 1 The percentage and number of circulating blood DCs from sepsis patients are selectively declined. Leukocytes from healthy donors and sepsis patients were obtained and directly stained for DC surface markers. (A) Gating strategy for the identification of human DC subsets from healthy donors (n = 18), sepsis 1-2d (n = 27) and sepsis 3-7d (n = 13). (B) The absolute number of each DC subset in per ml peripheral blood among the three groups. (C) Percentage of each DC subset among Lin-HLA-DR+ cell population among the three groups. (D) Percentage of each DC subset in leukocytes among the three groups. (E) Percentage of monocytes in leukocytes among the three groups: healthy donors (n = 30), sepsis 1-2d (n = 22) and sepsis 3-7d (n = 12). Error bars indicate mean ± SD. ***P < 0.001; ****P < 0.0001.
Sepsis Down-Regulates CD86 and HLA-DR on the Surface of PB DCs
The expression of antigen-presenting molecules (e.g., HLA-DR) and co-stimulatory molecules (e.g., CD86) on DCs is important to T cell priming in response to infection (41, 42). To this end, we examined the surface expression HLA-DR and CD86 on DCs derived from the PB of sepsis patients (Figure 2A). CD1c+ DCs from sepsis patients expressed lower levels of CD86 and HLA-DR during early stage of the disease and remained at significantly lower levels at the later stage compared to their counterparts in the healthy donors (Figure 2B). The expression of HLA-DR on the surface of pDCs derived from the children with sepsis in the early stage of disease was significantly lower compared with that of the health donor group, whereas the level of CD86 did not change significantly (Figure 2C). Therefore, sepsis also impairs DC maturation and activation, affecting CD1c+ cDCs to a greater extent. There are very few dendritic cells in human peripheral blood, and some cells will not survive overnight after stimulant, it is really difficult to detect the cytokine release function of dendritic cells on a technical level.
Figure 2 Sepsis down-regulates the expression of CD86 and HLA-DR on DCs in PB. (A) Flow cytometry histograms of CD86 and HLA-DR expression on each DC subset. (B, C) Percentage of CD86+ and HLA-DR+ cells on each DC subset from healthy donors (n = 20), sepsis 1-2d (n = 16) and sepsis 3-7d (n = 10). Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001.
Sepsis Induces DC Apoptosis
Previous studies have demonstrated that lymphocyte apoptosis is associated with immune deficiency in sepsis (43, 44). Both death-receptor- and mitochondrial-mediated pathways have been found to be responsible for sepsis-induced apoptosis, suggesting the engagement of multiple cell death stimuli (45). We hypothesized that sepsis-induced DC defects may be the result of increased rates of cell apoptosis. To address this possibility, we obtained PB from sepsis patients to examine DC apoptosis, and used healthy donors as controls. Flow cytometric analysis of Annexin-V and PI staining revealed live cells (Annexin-V−PI−), early apoptotic cells (Annexin-V+PI−), late apoptotic cells (Annexin-V+PI+), and necrotic cells (Annexin-V−PI+) (Figure 3A). We found that approximately 2% of CD1c+DCs and 5.5% of pDCs from sepsis patients at days 1 to 3 of diagnosis were late apoptotic cells, whereas healthy donors had approximately 6-fold and 3-fold fewer late apoptotic cells among the CD1c+ DC (0.3%) and pDC (1.4%) subsets, respectively (Figure 3C). From days 3 to 7 of sepsis, the frequency of late apoptotic cells among the CD1c+ DCs and pDCs was approximately 4-fold and 7-fold greater than that of healthy donors (Figures 3B, C). During the early apoptotic stage, we no significant difference in CD1c+ DCs and pDCs was observed between healthy donors and sepsis patients. In contrast, sepsis did not markedly affect the survival capability of monocytes (Figure 3D). These findings suggest that sepsis increases the rate of DC apoptotic cell death throughout the acute inflammation phase.
Figure 3 Sepsis patients exhibit increased levels of late apoptosis on DC subsets rather than on monocytes. (A) Flow detection of apoptosis of DC subsets. (B) Percentage of early apoptotic pDC and late apoptotic/dead pDC from healthy donors(n = 10), sepsis 1-2d (n = 16) and sepsis 3-7d (n = 8). (C) Percentage of early apoptotic CD1c+cDC and late apoptotic/dead CD1c+cDC from healthy donors (n = 10), sepsis 1-2d (n = 21) and sepsis 3-7d (n = 14). (D) Percentage of early apoptotic monocytes and late apoptotic/dead monocytes from healthy donors (n = 30), sepsis 1-2d (n = 22) and sepsis 3-7d (n = 12). Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001.
CDPs Dramatically Decrease During Sepsis
DCs develop from HSPCs in the BM. Under the steady-state conditions, HSCs give rise to multipotent progenitors (MPPs), which can become granulocyte macrophage DC progenitors (GMDPs), monocyte and DC progenitors (MDPs), and common DC progenitors (CDPs) (40). Of these, CDPs directly differentiate into both CD1c+DCs and pDCs (46–48). Therefore, we next asked whether the impaired generation of DC progenitors may contribute to DC defects in the PB during sepsis. Three major DC progenitors (i.e., GMDPs, MDPs and CDPs) were observed in the PB from sepsis patients and healthy donors (Figure 4A). Sepsis patients exhibited a significant decrease in the frequency of CDPs between days 1 to 7 post-diagnosis compared to the healthy donors (Figures 4B−D). In contrast, the sepsis patients showed an increased frequency and number of MDPs and GMDPs was potentially enhanced in vivo (Figure 4C). Thus, CDPs are more sensitive than GMDPs and MDPs to sepsis-mediated suppression.
Figure 4 Decreases in CDPs and increases in GMDPs from sepsis patients are observed. (A) Flow cytometry of human peripheral blood, showing the gating strategy of GMDPs, MDPs, CDPs. (B, C) The proportion of CDPs, MDPs and GMDPs in CD45RA+ cells and total leukocytes respectively from healthy donors (n = 18), sepsis 1-2d (n = 15) and sepsis 3-7d (n = 9). (D)The absolute number of CDPs, MDPs and GMDPs in per ml PB from healthy donors(n = 18), sepsis 1-2d (n = 15) and sepsis 3-7d (n = 8). Error bars indicate mean ± SD. *P < 0.05; ***P < 0.001; ****P < 0.0001.
Generation of Human CD1c+ cDCs and pDCs From Human HSPCs in Culture
To better understand the mechanisms by which inflammatory stimuli impact the generation of DC progenitors from HSPCs, we established an ex vivo culture method of producing DCs from human CD34+ HSPCs (Figure 5A) (40). On day 14 of culture, the cells were collected and stained for antibodies to identify DCs and DC subsets. CD66b and CD14 were used to exclude granulocytes and monocytes, respectively. CD1c+ DCs were CD66b-CD14- HLA-DR+ CD1c+ (Figure 5B). Upon stimulation with the TLR4 agonist, LPS, these cells significantly upregulated 80-fold more IL-12p35 mRNA (Figure 5C), suggesting the induction of CD1c+ DCs. pDCs are specialized cells that produce of high levels of IFN-α and IFN-β (49). We identified pDCs based on their CD66b-CD14-CD1c-CD123+CD303+ phenotype, sorted them into CD123+ and CD303+ cell subsets respectively, and stimulated them with R848 and CPG ODN for 2 h. mRNA was extracted from these pDCs to examine the expression of genes encoding IFN-α and IFN-β. Upon CpG stimulation, we observed that CD123+ pDCs rather than CD303+ cells, could rapidly upregulate the expression of mRNA encoding IFN-α and IFN-β (Figure 5D). Therefore, CD66b-CD14- HLA-DR+CD1c+ cDCs and CD66b-CD14-CD1c-CD123+ pDCs were used for all subsequent studies.
Figure 5 In vitro induction of DCs from HSPCs. (A) Workflow for the induction of HSPC-DCs. (B) Flow cytometry of pDCs (CD66b-CD14-CD1c-CD123+CD303-) and CD1c+cDCs (CD66b-CD14-CD1c+) populations after 14 days of induction from CD34+HSPCs. On day 14, (C) After stimulated with the TLR4 and TLR7 agonists for 2 hours, mRNA of FACS sorter purified CD1c+cDCs was extracted to measure gene expression using real time RT-PCR. (D) CD123+pDCs and CD303+pDCs were highly purified using FACs sorter. Then both populations were stimulated with the TLR7 and TLR9 for 2 hours, mRNA was collected to measure gene expression using real time RT-PCR. Error bars indicate mean ± SD. **P < 0.01; ***P < 0.001; ****P < 0.0001.
G-CSF Impairs the Generation of CD1c+cDCs and pDCs From HSPCs In Vitro
To identify the potential factors that impair DC generation in sepsis patients, we screened a panel of inflammatory cytokines known to play an important role in sepsis for their ability to affect DC induction in in vitro culture (Figure 6A). As shown in Figures 5B, C, the addition of LPS and IL-1β, which are known to be important factors that contribute to sepsis (28, 50), did not significantly affect DC generation from HSPCs (Figures 6B, C). G-CSF, which is also increased during acute inflammation (27, 28, 51), significantly reduced the number and frequency of CD1c+ DCs and pDCs in culture (Figures 6B, C). IFN-γ is a crucial pro-inflammatory cytokine that is produced in response to pathogen infection (52). Our results revealed that IFN-γ inhibited total DC proliferation, which primarily affected CD1c+ DCs. In light of the impact of IFN-γ on the differentiation of DC subsets, we were surprised to find that IFN-γ had different effects on CD1c+ DCs and pDCs, suppressing CD1c+ DCs but promoting pDC differentiation (Figures 6B, C). Notably, TNF-α profoundly increased pDC generation in culture (Figures 6B, C). Collectively, these data suggest that both G-CSF and IFN-γ have the capacity to impair DC generation from cultured HSPCs. Furthermore, IFN-γ inhibits CD1c+ DCs, but promotes pDC differentiation. Moreover, increased IL-12p35 and IFN-β production following stimulation with LPS/R848 further supports the observed impaired generation of authentic CD1c+ DCs and pDCs. (Figure 6D).
Figure 6 G-CSF and IFN-γ impaired the induction of HSPC-DCs subsets. (A) Flow cytometry of HSPC-DCs subset from various tested cytokines [e.g., IFN-γ (10ng/ml), IL-1β (10ng/ml), G-CSF (10ng/ml) and TNF-α (10ng/ml)] and LPS (10ng/ml), which were added into the culture system on day7. (B) The graphs showed the proliferation of HSPC-pDCs and CD1c+cDCs under various cytokines stimulation by day14. (C) The percentage of HSPC-pDCs and CD1c+ cDCs among total populations under various cytokine stimulation on day14. (D) Total HSPC-DCs were stimulated with the TLR4 and TLR7 agonists for 2 hours, mRNA was extracted to measure gene expression using real time RT-PCR. Data shown are representative of three independent experiments. Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
G-CSF Impairs the Expression of Pro-DC Transcription Factors in Cultured Human HSPCs In Vitro
We next examined whether G-CSF may affect the function of DCs generated in culture. It has been previously reported that G-CSF levels are associated with a poor clinical outcome in patients with sepsis (30–32). We found that unstimulated DCs generated in the presence of G-CSF expressed lower levels of HLA-DR compared to their counterparts produced in the absence of G-CSF (Figure 7A). This finding suggests that G-CSF may contribute to decreased HLA-DR expression on DCs in sepsis patients.
Figure 7 G-CSF impairs the expression of pro-DC development transcription factors in cultured human HSPCs in vitro. On D14 of culture, (A) HLA-DR expression on HSPC-DC subsets after G-CSF treatment for 7 days. (B) mRNA was collected to measure gene expression using real time RT-PCR. Results are representative of three independent experiments. Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
To examine the mechanisms associated with G-CSF-mediated suppression of DC generation from HSPCs, we examined the impact of G-CSF on the expression of transcription factors, including IRF8, IRF4, TCF4, BATF3, and ZBTB46. TCF4 and IRF4 are known to promote pDC development (53). In addition, Batf3 is highly important for cDC1 development (54), IRF4 determines CD1c+ cDC2 differentiation (55), and ZBTB46 has been identified as a marker of both cDC1 and cDC2 (56, 57). We assessed the level of transcription factor and Flt3 expression by real-time RT-PCR. FLT3 and the transcriptional factor, IRF8, are known to be important throughout the entire process of DC development (58–60). We found that G-CSF significantly reduced the expression of FLT3 and IRF8 (Figure 7B), which was consistent with the reduction of proliferation and differentiation of CD1c+ DCs and CD123+ pDCs. We also observed a marked decrease in the expression of the genes associated with cDCs (ZBTB46, IRF4, and BATF3) and pDCs (TCF4 and IRF4) (Figure 7B). CEBPA, which functions to promote myeloid differentiation (61, 62), was also increased (Figure 7B). These results indicate that G-CSF impairs pDC and CD1c+ cDC generation from HSPCs, likely through regulation of the key transcription factors required for DC development.
Discussion
In this study, we demonstrated that sepsis induces DC defects in pediatric patients. These defects are associated with the impaired generation of CDPs and increased apoptosis of DCs. Among the tested inflammation-associated cytokines, we found that both G-CSF and IFN-γ contribute to reduced DC generation from HSPCs in culture. Moreover, the addition of G-CSF significantly decreases the expression of transcription factors required for HSPC-derived DC production. Given the crucial role of DCs in both innate and adaptive immunity, our findings are important for gaining a better understanding of the pathology associated with sepsis-associated immune suppression in patients.
A lower number of DCs in sepsis appear to be associated with poor clinical outcomes. Guisset et al. and Grimaldi et al. have shown that sepsis patients with depleted circulating DCs are more likely to develop septic shock, and can even predict higher mortality rates in fetal sepsis (9, 11). Our study found that increased DC apoptosis and death can in part explain the depletion of DCs. During inflammation, the local microenvironment, especially inflammatory cytokines, is important for the regulation of DC function and survival (63, 64). The study by Raffray et al. demonstrated that the serum from patients with sepsis induced higher DC death compared to serum from normal healthy donors or patients with cardiogenic shock (65). Furthermore, accumulating evidence has shown that inflammatory factors (e.g., G-CSF, IFN-γ, TNF-α, IL-6, IL-10, and TGF-β) can cause DC impairment and dysfunction, even inducing the apoptosis of DCs (13–22). Our results showed that DC apoptosis occurred during sepsis.
In addition to apoptosis, we also provide evidence that sepsis may have a significant impact on the differentiation of DC progenitors into DCs. This represents another mechanism by which sepsis causes a reduction of DCs. Our findings are supported by observations in mouse models. For example, Pasquevich et al. and Beshara et al. reported that BM CDPs were reduced in mice infected with Ye/Ec/Sa/Lm (Yersinia enterocolitica/Escherichia coli/Staphylococcus aureus/Listeria monocytogenes) (66) and influenza A virus (IVA), respectively (67). Conversely, the study by Macal et al. showed that CDPs appeared to increase on day 5, but were subsequently reduced in mice during infection with chronic lymphocytic choriomeningitis virus (68). This disparity may be due to different timings of examination and infection models. Collectively, our studies and these of others indicate that sepsis may have a significant impact on hematopoiesis and DC development in the BM. To our knowledge, our study is the first to report that DC progenitors are decreased in the PB of sepsis patients. Our results further reveal a possible underlying cause of this defect may be due to enhanced myelopoiesis (e.g., monocytes and granulocytes), increased circulating GMDPs and MDP production. Several studies have reported an increase in neutrophils and monocytes during sepsis (69–71). This primarily results from ‘emergency hematopoiesis’ characterized by converting the hematopoietic response program to replenish depleted granulocytes and monocytes following a systemic infection (25).
Although we have explored the reduction of DCs associated with increased apoptosis and impaired generation of DC progenitors, we cannot rule out the possibility that decreased DCs in the PB may be attributable to the altered migration capacity of DCs, which cannot be investigated in humans.
Our findings reveal that sepsis impairs the number and antigen-presentation functionality of DCs, leading to a reduction in immature DCs, which may further perpetuate immunosuppression. DCs display an immature phenotype under steady state conditions. Following stimulation with microbes or danger signals, DCs undergo activation and maturation through a series of phenotypic and functional changes, including the upregulation of the expression of surface MHC-II and co-stimulatory molecule CD86 (72, 73). We found that the downregulation of these molecules suggests a defect in the antigen-presenting capacity of DCs, which is to a large extent influenced by the microenvironment as previously discussed (13–22). These tolerogenic immature DCs impair the ability of the immune system to mount a T cell response against secondary infections (74–76). Some studies have demonstrated that tolerogenic DCs are decreased in sepsis, which are susceptible to secondary infection, even if critically ill patients recover from systemic inflammatory response syndrome (SIRS) (11, 77). Thus, the downregulation of HLA-DR and CD86 are suggestive of a state of immune suppression in sepsis (78). Consistent with our observations, the studies by Grimaldi et al. (11) and Poehlmann et al. (6) showed that cDCs exhibit lower expression of HLA-DR, whereas there was no difference in its expression on pDCs in patients with sepsis. This difference may be due to the low expression of MHC-II and co-stimulatory molecules on pDCs (79). It is likely that CD1c+ DCs are more sensitive than pDCs for predicting the severity of sepsis. Future studies will use a larger cohort of patients to strengthen our conclusion.
We also report for the first time, that G-CSF markedly suppresses the generation and functionality of CD1c+ DCs and pDCs. Recent reports show that G-CSF not only mobilizes HSCs from the BM into the peripheral blood, but also modifies the bone marrow microenvironment (80, 81). In addition to the observation that G-CSF facilitates the proliferation, differentiation, and maturation of neutrophils to treat or prevent neutropenia in clinical patients (82–85), our results demonstrated that G-CSF inhibited the differentiation and proliferation of CD1c+ DCs and pDCs. In contrast to our results, Shaughnessy et al. showed that the administration of G-CSF in eight patients with graft-versus-host disease (GVHD) could mobilize more pDCs into the PB (86). The discrepancy may result from DC development modulated by the complex in vivo environment, whereas our research focuses on the effect of the signaling of G-CSF on DC development. We also found that G-CSF could impair the activation and maturation of DCs by HLA-DR, as well as the cytokine secretion function of DCs (e.g., IL-12, and IFN-β). Similar to our results, Reddy et al. reported that the administration of G-CSF to mice resulted in donor DCs that produced low levels of TNF-α and IL-12 in acute GVHD (22). Another study reported that G-CSF-stimulated PBMCs of healthy donors contained predominantly T helper 2-inducing DCs (19, 87). These results suggest that G-CSF may alter DC functionality. The impact of G-CSF on HSC differentiation into DCs has not been previously examined in-depth. Our results demonstrate that G-CSF inhibited the differentiation and development of CD1c+ DCs and pDCs. These results prompted us to investigate DC depletion when sepsis patients were administrated G-CSF as a treatment for neutropenia.
Furthermore, our results demonstrate that G-CSF is associated with key transcriptional factors required for DC development. Our results showed that both FLT3 and IRF8 expression regulating the DC development were decreased. Similarly, the expression of genes that regulate cDCs (ZBTB46, BATF3, and IRF4) and pDCs (TCF4 and IRF4), respectively, were also declined. However, the gene, CEBPA, which promotes granulopoiesis, was increased. These findings suggest that G-CSF may play a dual role, promoting granulocyte lineage differentiation (71, 88, 89), as well as inhibiting DC development and functionality. Additional studies are needed to elucidate the mechanism by which G-CSF regulates these DC-related transcriptional factors.
Our results indicate that the pro-inflammatory factor, IFN-γ, also plays an important role in the differentiation and development of DCs. Previous studies have reported that IFN-γ has a pro-inflammatory potential in sepsis (90, 91) and can even drive immune suppression and induce secondary infections (33). Moreover, many studies have shown that IFN-γ directly regulates the differentiation and function of HSCs during infection, but not during steady-state hematopoiesis (37, 92, 93). For example, during acute lymphocytic choriomeningitis virus (LVMV) infection, IFN-γ impairs HSC self-renewal and restoration of the number of HSCs (93). During a chronic infection, IFN-γ activates quiescent HSCs (37) and induces myeloid differentiation to defend against infection (92, 94). In addition, it has been reported that IFN-γ may upregulate the expression of MHC-class I/II on DCs and promote the production of cytokines important for T cell-mediated immune responses. Indeed, a lack of IFN-γ signaling in mature IFNR-/- DCs results in the reduced expression of intercellualr cell adhesion molecule-1 (ICAM-1), CD86, IL-1β, and IL-12p70 (95, 96). In addition to its role in DC activation during the acute phase of sepsis, IFN-γ can exert tolerogenic effects in DCs during the later phase (18, 97). There are currently a limited number of reports that have investigated the effects of IFN-γ on the generation of DC subsets. Consistent with our study, Laustsen et al. found that IFN-γ priming promoted HSPC generation of pDCs (98). Interestingly, we also found that IFN-γ mainly suppresses CD1c+ DC proliferation and differentiation. To our knowledge, this is the first report describing this effect of IFN-γ on CD1c+ DC generation.
In conclusion, our study demonstrates that the impaired generation of CDPs and increased apoptosis rates of DCs contribute to the DC defects observed in sepsis patients. It is likely that the production of G-CSF and IFN-γ during sepsis plays an important role in suppressing DC development and differentiation. These findings may have important implications for improving the understanding of both the pathology and immunosuppression associated with sepsis.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics Statement
The studies involving human participants were reviewed and approved by Medical Ethics Committee of the Children’s Hospital of Soochow University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.
Author Contributions
JL, KS, LM, JH, and ZB conceived and designed the project. JL, KS, HY, DF, HH, and HY performed experiments. JL, KS, HZ, FF, YL, SW, LM, JH, and ZB analyzed and interpreted the data. JL, LM, JH, and ZB wrote the manuscript. JL, KS, HZ, FF, YL, SW, LM, JH, and ZB edited the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The work was supported by National Natural Science Foundation (Grant number 81971867), Science and Technology Project of Jiangsu Province (BE2019672), the Natural Science Foundation of Jiangsu Province (Grant BK20190053), the Medical Science Program of Jiangsu Province (Grant H2019002), the Science and Technology Program of Suzhou (Grant SYS2018067) and Health Talent Training Program of Suzhou (GSWS2020044).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
The authors thank Yi Zhang for his advice and help with the manuscript.
Abbreviations
DC, dendritic cell; HSPC, hematopoietic stem and progenitor cell; cDC, conventional DC; pDC, plasmacytoid DC; PB, peripheral blood; HLA-DR, human leukocyte antigen DR; APC, antigen presentation cell; MPP, multipotent progenitor; CMP, common myeloid progenitor; GMDP, granulocyte macrophage DC progenitor; MDP, monocyte and DC progenitor; CDP, common DC progenitor; Ye, Yersinia enterocolitica; Ec, Escherichia coli; Sa, Staphylococcus aureus; Lm, Listeria monocytogenes; IVA, influenza A virus; HIV, human immunodeficiency virus; LVMV, Lymphocytic choriomeningitis virus; GVHD, Graft-versus-host disease; SIRS, Systemic inflammatory response syndrome; MODS, Multiple Organ Dysfunction syndrome; PRISM-III, pediatric risk of mortality score-III; IL-1β, interleukin-1β; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; G-CSF, granulocyte-Colony stimulating factor; LPS, lipopolysaccharide; IL-10, interleukin-10; TGF-β, transforming growth factor-β; FLT3L, FMS-like tyrosine kinase 3 ligand; SCF, stem cell factor; IL-3, interleukin-3; TPO, thermoplastic polyolefin; PD-L1, programmed cell death-Ligand 1; IDO, indoleamine 2,3-dioxugenase.
Glossary
References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA (2016) 315(8):801–10. doi: 10.1001/jama.2016.0287
2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet (2020) 395(10219):200–11. doi: 10.1016/S0140-6736(19)32989-7
3. Reizis B. Classical Dendritic Cells as a Unique Immune Cell Lineage. J Exp Med (2012) 209(6):1053–6. doi: 10.1084/jem.20121038
4. Baratin M, Foray C, Demaria O, Habbeddine M, Pollet E, Maurizio J, et al. Homeostatic NF-kappaB Signaling in Steady-State Migratory Dendritic Cells Regulates Immune Homeostasis and Tolerance. Immunity (2015) 42(4):627–39. doi: 10.1016/j.immuni.2015.03.003
5. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, et al. Dendritic Cell PAR1-S1P3 Signalling Couples Coagulation and Inflammation. Nature (2008) 452(7187):654–8. doi: 10.1038/nature06663
6. Poehlmann H, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. Phenotype Changes and Impaired Function of Dendritic Cell Subsets in Patients With Sepsis: A Prospective Observational Analysis. Crit Care (2009) 13(4):R119. doi: 10.1186/cc7969
7. Collin M, Bigley V. Human Dendritic Cell Subsets: An Update. Immunology (2018) 154(1):3–20. doi: 10.1111/imm.12888
8. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in Sepsis: A Novel Understanding of the Disorder and a New Therapeutic Approach. Lancet Infect Dis (2013) 13(3):260–8. doi: 10.1016/S1473-3099(13)70001-X
9. Guisset O, Dilhuydy MS, Thiebaut R, Lefevre J, Camou F, Sarrat A, et al. Decrease in Circulating Dendritic Cells Predicts Fatal Outcome in Septic Shock. Intensive Care Med (2007) 33(1):148–52. doi: 10.1007/s00134-006-0436-7
10. Tinsley KW, Grayson MH, Swanson PE, Drewry AM, Chang KC, Karl IE, et al. Sepsis Induces Apoptosis and Profound Depletion of Splenic Interdigitating and Follicular Dendritic Cells. J Immunol (2003) 171(2):909–14. doi: 10.4049/jimmunol.171.2.909
11. Grimaldi D, Louis S, Pene F, Sirgo G, Rousseau C, Claessens YE, et al. Profound and Persistent Decrease of Circulating Dendritic Cells Is Associated With ICU-Acquired Infection in Patients With Septic Shock. Intensive Care Med (2011) 37(9):1438–46. doi: 10.1007/s00134-011-2306-1
12. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host Innate Immune Responses to Sepsis. Virulence (2014) 5(1):36–44. doi: 10.4161/viru.25436
13. Mittal SK, Roche PA. Suppression of Antigen Presentation by IL-10. Curr Opin Immunol (2015) 34:22–7. doi: 10.1016/j.coi.2014.12.009
14. Alter G, Kavanagh D, Rihn S, Luteijn R, Brooks D, Oldstone M, et al. IL-10 Induces Aberrant Deletion of Dendritic Cells by Natural Killer Cells in the Context of HIV Infection. J Clin Invest (2010) 120(6):1905–13. doi: 10.1172/JCI40913
15. Kelly A, Houston SA, Sherwood E, Casulli J, Travis MA. Regulation of Innate and Adaptive Immunity by TGFbeta. Adv Immunol (2017) 134:137–233. doi: 10.1016/bs.ai.2017.01.001
16. Winkler MS, Rissiek A, Priefler M, Schwedhelm E, Robbe L, Bauer A, et al. Human Leucocyte Antigen (HLA-DR) Gene Expression Is Reduced in Sepsis and Correlates With Impaired TNFalpha Response: A Diagnostic Tool for Immunosuppression? PloS One (2017) 12(8):e0182427. doi: 10.1371/journal.pone.0182427
17. Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, et al. Interleukin-6/STAT3 Signaling as a Promising Target to Improve the Efficacy of Cancer Immunotherapy. Cancer Sci (2017) 108(10):1947–52. doi: 10.1111/cas.13332
18. Flohe SB, Agrawal H, Flohe S, Rani M, Bangen JM, Schade FU. Diversity of Interferon Gamma and Granulocyte-Macrophage Colony-Stimulating Factor in Restoring Immune Dysfunction of Dendritic Cells and Macrophages During Polymicrobial Sepsis. Mol Med (2008) 14(5-6):247–56. doi: 10.2119/2007-00120.Flohe
19. Klangsinsirikul P, Russell NH. Peripheral Blood Stem Cell Harvests From G-CSF-Stimulated Donors Contain a Skewed Th2 CD4 Phenotype and a Predominance of Type 2 Dendritic Cells. Exp Hematol (2002) 30(5):495–501. doi: 10.1016/s0301-472x(02)00785-3
20. Luft T, Jefford M, Luetjens P, Hochrein H, Masterman KA, Maliszewski C, et al. IL-1 Beta Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation. J Immunol (2002) 168(2):713–22. doi: 10.4049/jimmunol.168.2.713
21. Morrison RS 3rd, Cruse JM, Wang H, Lewis RE. Dendritic Cell Differentiation and Proliferation: Enhancement by Tumor Necrosis Factor-Alpha. Exp Mol Pathol (2003) 75(3):228–37. doi: 10.1016/s0014-4800(03)00087-x
22. Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, et al. G-CSF Modulates Cytokine Profile of Dendritic Cells and Decreases Acute Graft-Versus-Host Disease Through Effects on the Donor Rather Than the Recipient. Transplantation (2000) 69(4):691–3. doi: 10.1097/00007890-200002270-00041
23. Merad M, Sathe P, Helft J, Miller J, Mortha A. The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting. Annu Rev Immunol (2013) 31:563–604. doi: 10.1146/annurev-immunol-020711-074950
24. Dress RJ, Wong AY, Ginhoux F. Homeostatic Control of Dendritic Cell Numbers and Differentiation. Immunol Cell Biol (2018) 96(5):463–76. doi: 10.1111/imcb.12028
25. Boettcher S, Manz MG. Regulation of Inflammation- and Infection-Driven Hematopoiesis. Trends Immunol (2017) 38(5):345–57. doi: 10.1016/j.it.2017.01.004
26. Panopoulos AD, Watowich SS. Granulocyte Colony-Stimulating Factor: Molecular Mechanisms of Action During Steady State and ’Emergency’ Hematopoiesis. Cytokine (2008) 42(3):277–88. doi: 10.1016/j.cyto.2008.03.002
27. Reilly JP, Anderson BJ, Hudock KM, Dunn TG, Kazi A, Tommasini A, et al. Neutropenic Sepsis Is Associated With Distinct Clinical and Biological Characteristics: A Cohort Study of Severe Sepsis. Crit Care (2016) 20(1):222. doi: 10.1186/s13054-016-1398-y
28. Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. Multiplex Cytokine Profiling in Patients With Sepsis. APMIS (2011) 119(2):155–63. doi: 10.1111/j.1600-0463.2010.02705.x
29. Roberts AW. G-CSF: A Key Regulator of Neutrophil Production, But That’s Not All! Growth Factors (2005) 23(1):33–41. doi: 10.1080/08977190500055836
30. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine Profiles as Markers of Disease Severity in Sepsis: A Multiplex Analysis. Crit Care (2007) 11(2):R49. doi: 10.1186/cc5783
31. Ishikawa K, Tanaka H, Nakamori Y, Hosotsubo H, Ogura H, Nishino M, et al. Difference in the Responses After Administration of Granulocyte Colony-Stimulating Factor in Septic Patients With Relative Neutropenia. J Trauma (2000) 48(5):814–24. doi: 10.1097/00005373-200005000-00004
32. Tanaka H, Ishikawa K, Nishino M, Shimazu T, Yoshioka T. Changes in Granulocyte Colony-Stimulating Factor Concentration in Patients With Trauma and Sepsis. J Trauma (1996) 40(5):718–25; discussion 25-6. doi: 10.1097/00005373-199605000-00006
33. Kim EY, Ner-Gaon H, Varon J, Cullen AM, Guo J, Choi J, et al. Post-Sepsis Immunosuppression Depends on NKT Cell Regulation of mTOR/IFN-Gamma in NK Cells. J Clin Invest (2020) 130(6):3238–52. doi: 10.1172/JCI128075
34. Li Q, Wu C, Liu Z, Zhang H, Du Y, Liu Y, et al. Increased TLR4 Expression Aggravates Sepsis by Promoting IFN-Gamma Expression in CD38(-/-) Mice. J Immunol Res (2019) 2019:3737890. doi: 10.1155/2019/3737890
35. Tian Y, Meng L, Wang Y, Li B, Yu H, Zhou Y, et al. Graft-Versus-Host Disease Depletes Plasmacytoid Dendritic Cell Progenitors to Impair Tolerance Induction. J Clin Invest (2021) 131(1):e136774. doi: 10.1172/JCI136774
36. MacNamara KC, Jones M, Martin O, Winslow GM. Transient Activation of Hematopoietic Stem and Progenitor Cells by IFNgamma During Acute Bacterial Infection. PloS One (2011) 6(12):e28669. doi: 10.1371/journal.pone.0028669
37. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent Haematopoietic Stem Cells are Activated by IFN-Gamma in Response to Chronic Infection. Nature (2010) 465(7299):793–7. doi: 10.1038/nature09135
38. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med (2017) 45(3):486–552. doi: 10.1097/CCM.0000000000002255
39. Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, et al. The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol (2016) 196(3):1070–80. doi: 10.4049/jimmunol.1501310
40. Lee J, Zhou YJ, Ma W, Zhang W, Aljoufi A, Luh T, et al. Lineage Specification of Human Dendritic Cells Is Marked by IRF8 Expression in Hematopoietic Stem Cells and Multipotent Progenitors. Nat Immunol (2017) 18(8):877–88. doi: 10.1038/ni.3789
41. Banchereau J, Steinman RM. Dendritic Cells and the Control of Immunity. Nature (1998) 392(6673):245–52. doi: 10.1038/32588
42. Elmetwali T, Salman A, Wei W, Hussain SA, Young LS, Palmer DH. CD40L Membrane Retention Enhances the Immunostimulatory Effects of CD40 Ligation. Sci Rep (2020) 10(1):342. doi: 10.1038/s41598-019-57293-y
43. Hotchkiss RS, Monneret G, Payen D. Sepsis-Induced Immunosuppression: From Cellular Dysfunctions to Immunotherapy. Nat Rev Immunol (2013) 13(12):862–74. doi: 10.1038/nri3552
44. Girardot T, Rimmele T, Venet F, Monneret G. Apoptosis-Induced Lymphopenia in Sepsis and Other Severe Injuries. Apoptosis (2017) 22(2):295–305. doi: 10.1007/s10495-016-1325-3
45. Chang KC, Unsinger J, Davis CG, Schwulst SJ, Muenzer JT, Strasser A, et al. Multiple Triggers of Cell Death in Sepsis: Death Receptor and Mitochondrial-Mediated Apoptosis. FASEB J (2007) 21(3):708–19. doi: 10.1096/fj.06-6805com
46. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of Clonogenic Common Flt3+M-CSFR+ Plasmacytoid and Conventional Dendritic Cell Progenitors in Mouse Bone Marrow. Nat Immunol (2007) 8(11):1207–16. doi: 10.1038/ni1518
47. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. In Vivo Analysis of Dendritic Cell Development and Homeostasis. Science (2009) 324(5925):392–7. doi: 10.1126/science.1170540
48. Naik SH, Sathe P, Park HY, Metcalf D, Proietto AI, Dakic A, et al. Development of Plasmacytoid and Conventional Dendritic Cell Subtypes From Single Precursor Cells Derived In Vitro and In Vivo. Nat Immunol (2007) 8(11):1217–26. doi: 10.1038/ni1522
49. Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M. Plasmacytoid Dendritic Cells: One-Trick Ponies or Workhorses of the Immune System? Nat Rev Immunol (2011) 11(8):558–65. doi: 10.1038/nri3027
50. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm. Microbiol Mol Biol Rev (2012) 76(1):16–32. doi: 10.1128/MMBR.05015-11
51. Presneill JJ, Waring PM, Layton JE, Maher DW, Cebon J, Harley NS, et al. Plasma Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Levels in Critical Illness Including Sepsis and Septic Shock: Relation to Disease Severity, Multiple Organ Dysfunction, and Mortality. Crit Care Med (2000) 28(7):2344–54. doi: 10.1097/00003246-200007000-00028
52. de Bruin AM, Voermans C, Nolte MA. Impact of Interferon-Gamma on Hematopoiesis. Blood (2014) 124(16):2479–86. doi: 10.1182/blood-2014-04-568451
53. Amon L, Lehmann CHK, Baranska A, Schoen J, Heger L, Dudziak D. Transcriptional Control of Dendritic Cell Development and Functions. Int Rev Cell Mol Biol (2019) 349:55–151. doi: 10.1016/bs.ircmb.2019.10.001
54. Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, Klekotka PA, et al. Peripheral CD103+ Dendritic Cells Form a Unified Subset Developmentally Related to CD8alpha+ Conventional Dendritic Cells. J Exp Med (2010) 207(4):823–36. doi: 10.1084/jem.20091627
55. Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, et al. Transcriptional Programming of Dendritic Cells for Enhanced MHC Class II Antigen Presentation. Nat Immunol (2014) 15(2):161–7. doi: 10.1038/ni.2795
56. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, et al. Expression of the Zinc Finger Transcription Factor zDC (Zbtb46, Btbd4) Defines the Classical Dendritic Cell Lineage. J Exp Med (2012) 209(6):1153–65. doi: 10.1084/jem.20112675
57. Satpathy AT, Kc W, Albring JC, Edelson BT, Kretzer NM, Bhattacharya D, et al. Zbtb46 Expression Distinguishes Classical Dendritic Cells and Their Committed Progenitors From Other Immune Lineages. J Exp Med (2012) 209(6):1135–52. doi: 10.1084/jem.20120030
58. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 Mutations and Human Dendritic-Cell Immunodeficiency. N Engl J Med (2011) 365(2):127–38. doi: 10.1056/NEJMoa1100066
59. Schraml BU, Reis e Sousa C. Defining Dendritic Cells. Curr Opin Immunol (2015) 32:13–20. doi: 10.1016/j.coi.2014.11.001
60. Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, et al. The Origin and Development of Nonlymphoid Tissue CD103+ DCs. J Exp Med (2009) 206(13):3115–30. doi: 10.1084/jem.20091756
61. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of Hematopoietic Stem Cell Repopulating Capacity and Self-Renewal in the Absence of the Transcription Factor C/EBP Alpha. Immunity (2004) 21(6):853–63. doi: 10.1016/j.immuni.2004.11.006
62. Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, et al. CEBPA-Double-Mutated Acute Myeloid Leukemia Displays a Unique Phenotypic Profile: A Reliable Screening Method and Insight Into Biological Features. Haematologica (2017) 102(3):529–40. doi: 10.3324/haematol.2016.151910
63. Roozendaal R, Mebius RE. Stromal Cell-Immune Cell Interactions. Annu Rev Immunol (2011) 29:23–43. doi: 10.1146/annurev-immunol-031210-101357
64. Qian C, Cao X. Dendritic Cells in the Regulation of Immunity and Inflammation. Semin Immunol (2018) 35:3–11. doi: 10.1016/j.smim.2017.12.002
65. Raffray L, Douchet I, Augusto JF, Youssef J, Contin-Bordes C, Richez C, et al. Septic Shock Sera Containing Circulating Histones Induce Dendritic Cell-Regulated Necrosis in Fatal Septic Shock Patients. Crit Care Med (2015) 43(4):e107–16. doi: 10.1097/CCM.0000000000000879
66. Pasquevich KA, Bieber K, Gunter M, Grauer M, Potz O, Schleicher U, et al. Innate Immune System Favors Emergency Monopoiesis at the Expense of DC-Differentiation to Control Systemic Bacterial Infection in Mice. Eur J Immunol (2015) 45(10):2821–33. doi: 10.1002/eji.201545530
67. Beshara R, Sencio V, Soulard D, Barthelemy A, Fontaine J, Pinteau T, et al. Alteration of Flt3-Ligand-Dependent De Novo Generation of Conventional Dendritic Cells During Influenza Infection Contributes to Respiratory Bacterial Superinfection. PloS Pathog (2018) 14(10):e1007360. doi: 10.1371/journal.ppat.1007360
68. Macal M, Jo Y, Dallari S, Chang AY, Dai J, Swaminathan S, et al. Self-Renewal and Toll-Like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells During Chronic Viral Infection. Immunity (2018) 48(4):730–44 e5. doi: 10.1016/j.immuni.2018.03.020
69. Uhel F, Azzaoui I, Gregoire M, Pangault C, Dulong J, Tadie JM, et al. Early Expansion of Circulating Granulocytic Myeloid-Derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients With Sepsis. Am J Respir Crit Care Med (2017) 196(3):315–27. doi: 10.1164/rccm.201606-1143OC
70. Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An Immune-Cell Signature of Bacterial Sepsis. Nat Med (2020) 26(3):333–40. doi: 10.1038/s41591-020-0752-4
71. Manz MG, Boettcher S. Emergency Granulopoiesis. Nat Rev Immunol (2014) 14(5):302–14. doi: 10.1038/nri3660
72. Laudanski K. Adoptive Transfer of Naive Dendritic Cells in Resolving Post-Sepsis Long-Term Immunosuppression. Med Hypotheses (2012) 79(4):478–80. doi: 10.1016/j.mehy.2012.06.028
73. Reis e Sousa C. Dendritic Cells in a Mature Age. Nat Rev Immunol (2006) 6(6):476–83. doi: 10.1038/nri1845
74. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, et al. Systemic Activation of Dendritic Cells by Toll-Like Receptor Ligands or Malaria Infection Impairs Cross-Presentation and Antiviral Immunity. Nat Immunol (2006) 7(2):165–72. doi: 10.1038/ni1300
75. Young LJ, Wilson NS, Schnorrer P, Mount A, Lundie RJ, La Gruta NL, et al. Dendritic Cell Preactivation Impairs MHC Class II Presentation of Vaccines and Endogenous Viral Antigens. Proc Natl Acad Sci USA (2007) 104(45):17753–8. doi: 10.1073/pnas.0708622104
76. Roquilly A, Villadangos JA. The Role of Dendritic Cell Alterations in Susceptibility to Hospital-Acquired Infections During Critical-Illness Related Immunosuppression. Mol Immunol (2015) 68(2 Pt A):120–3. doi: 10.1016/j.molimm.2015.06.030
77. Bouras M, Asehnoune K, Roquilly A. Contribution of Dendritic Cell Responses to Sepsis-Induced Immunosuppression and to Susceptibility to Secondary Pneumonia. Front Immunol (2018) 9:2590. doi: 10.3389/fimmu.2018.02590
78. Venet F, Monneret G. Advances in the Understanding and Treatment of Sepsis-Induced Immunosuppression. Nat Rev Nephrol (2018) 14(2):121–37. doi: 10.1038/nrneph.2017.165
79. Villadangos JA, Young L. Antigen-Presentation Properties of Plasmacytoid Dendritic Cells. Immunity (2008) 29(3):352–61. doi: 10.1016/j.immuni.2008.09.002
80. Roseren F, Pithioux M, Robert S, Balasse L, Guillet B, Lamy E, et al. Systemic Administration of G-CSF Accelerates Bone Regeneration and Modulates Mobilization of Progenitor Cells in a Rat Model of Distraction Osteogenesis. Int J Mol Sci (2021) 22(7):3505. doi: 10.3390/ijms22073505
81. Ok Bozkaya I, Azik F, Tavil B, Koksal Y, Ozguner M, Tunc B, et al. The Effect of Granulocyte Colony-Stimulating Factor on Immune-Modulatory Cytokines in the Bone Marrow Microenvironment and Mesenchymal Stem Cells of Healthy Donors. Biol Blood Marrow Transplant (2015) 21(11):1888–94. doi: 10.1016/j.bbmt.2015.08.007
82. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF Induces Stem Cell Mobilization by Decreasing Bone Marrow SDF-1 and Up-Regulating CXCR4. Nat Immunol (2002) 3(7):687–94. doi: 10.1038/ni813
83. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol (2006) 24(19):3187–205. doi: 10.1200/JCO.2006.06.4451
84. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. J Clin Oncol (2005) 23(18):4198–214. doi: 10.1200/JCO.2005.05.645
85. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 Update of EORTC Guidelines for the Use of Granulocyte-Colony Stimulating Factor to Reduce the Incidence of Chemotherapy-Induced Febrile Neutropenia in Adult Patients With Lymphoproliferative Disorders and Solid Tumours. Eur J Cancer (2011) 47(1):8–32. doi: 10.1016/j.ejca.2010.10.013
86. Shaughnessy PJ, Bachier C, Lemaistre CF, Akay C, Pollock BH, Gazitt Y. Granulocyte Colony-Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte-Macrophage Colony-Stimulating Factor With No Polarization of Dendritic Cell Subsets in Normal Donors. Stem Cells (2006) 24(7):1789–97. doi: 10.1634/stemcells.2005-0492
87. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-Colony Stimulating Factor Mobilizes T Helper 2-Inducing Dendritic Cells. Blood (2000) 95(8):2484–90. doi: 10.1182/blood.V95.8.2484
88. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol (2015) 195(4):1341–9. doi: 10.4049/jimmunol.1500861
89. Gregory AD, Hogue LA, Ferkol TW, Link DC. Regulation of Systemic and Local Neutrophil Responses by G-CSF During Pulmonary Pseudomonas Aeruginosa Infection. Blood (2007) 109(8):3235–43. doi: 10.1182/blood-2005-01-015081
90. Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, et al. The Role of Interferon-Gamma in the Pathogenesis of Acute Intra-Abdominal Sepsis. J Leukoc Biol (2010) 88(4):725–35. doi: 10.1189/jlb.0509307
91. Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-Alpha and IFN-Gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell (2021) 184(1):149–68.e17. doi: 10.1016/j.cell.2020.11.025
92. MacNamara KC, Oduro K, Martin O, Jones DD, McLaughlin M, Choi K, et al. Infection-Induced Myelopoiesis During Intracellular Bacterial Infection Is Critically Dependent Upon IFN-Gamma Signaling. J Immunol (2011) 186(2):1032–43. doi: 10.4049/jimmunol.1001893
93. de Bruin AM, Demirel O, Hooibrink B, Brandts CH, Nolte MA. Interferon-Gamma Impairs Proliferation of Hematopoietic Stem Cells in Mice. Blood (2013) 121(18):3578–85. doi: 10.1182/blood-2012-05-432906
94. Goedhart M, Cornelissen AS, Kuijk C, Geerman S, Kleijer M, van Buul JD, et al. Interferon-Gamma Impairs Maintenance and Alters Hematopoietic Support of Bone Marrow Mesenchymal Stromal Cells. Stem Cells Dev (2018) 27(9):579–89. doi: 10.1089/scd.2017.0196
95. Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, et al. Interferon-Gamma Is an Autocrine Mediator for Dendritic Cell Maturation. Immunol Lett (2004) 94(1-2):141–51. doi: 10.1016/j.imlet.2004.05.003
96. Alspach E, Lussier DM, Schreiber RD. Interferon Gamma and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol (2019) 11(3):a028480. doi: 10.1101/cshperspect.a028480
97. Rozman P, Svajger U. The Tolerogenic Role of IFN-Gamma. Cytokine Growth Factor Rev (2018) 41:40–53. doi: 10.1016/j.cytogfr.2018.04.001
Keywords: sepsis, dendritic cells, dendritic cell progenitors, common dendritic cell progenitors, G-CSF, IFN-γ
Citation: Lu J, Sun K, Yang H, Fan D, Huang H, Hong Y, Wu S, Zhou H, Fang F, Li Y, Meng L, Huang J and Bai Z (2021) Sepsis Inflammation Impairs the Generation of Functional Dendritic Cells by Targeting Their Progenitors. Front. Immunol. 12:732612. doi: 10.3389/fimmu.2021.732612
Received: 30 June 2021; Accepted: 23 August 2021;
Published: 09 September 2021.
Edited by:
Katsuaki Sato, University of Miyazaki, JapanReviewed by:
Nobuyuki Onai, Kanazawa Medical University, JapanShin Mineishi, Penn State Milton S. Hershey Medical Center, United States
Copyright © 2021 Lu, Sun, Yang, Fan, Huang, Hong, Wu, Zhou, Fang, Li, Meng, Huang and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jie Huang, j.shuang@163.com; Zhenjiang Bai, bbyshu@hotmail.com
†These authors have contributed equally to this work